According to the present invention there is provided a polymer comprising at least one antiseptic/analgesic/anti-inflammatory monomeric unit in conjunction with at least three further monomeric units, said three further monomeric units eliciting properties selected from the group consisting of: temperature activation, water solubility, mechanical strength, protein/polysaccharide bonding capacity, and combinations thereof. In particular, disclosed herein is a polymer, wherein: the water-soluble monomeric unit is a hydrophilic ethylene glycol (OEGMA) moiety; the mechanical strength-conferring monomeric unit is polylactide-co-2-hydroxy-ethyl-methyl acrylate (PLA/HEMA); the protein-reactive monomeric unit is an N-acryloxysuccinimide (NAS) moiety; and the thermosetting monomeric unit is an N-isopropyl acrylamide (NIPAAm) moiety. The anti-septic/analgesic/anti-inflammatory monomeric unit comprises a methacrylic ester derivative of salicylic acid (5-HMA or 4-HMA, or a combination thereof).

According to the present invention there is provided a polymer comprising at least one antiseptic/analgesic/anti-inflammatory monomeric unit in conjunction with at least three further monomeric units, said three further monomeric units eliciting properties selected from the group consisting of: temperature activation, water solubility, mechanical strength, protein/polysaccharide bonding capacity, and combinations thereof. In particular, disclosed herein is a polymer, wherein: the water-soluble monomeric unit is a hydrophilic ethylene glycol (OEGMA) moiety; the mechanical strength-conferring monomeric unit is polylactide-co-2-hydroxy-ethyl-methyl acrylate (PLA/HEMA); the protein-reactive monomeric unit is an N-acryloxysuccinimide (NAS) moiety; and the thermosetting monomeric unit is an N-isopropyl acrylamide (NIPAAm) moiety. The anti-septic/analgesic/anti-inflammatory monomeric unit comprises a methacrylic ester derivative of salicylic acid (5-HMA or 4-HMA, or a combination thereof).

Herein is described an oxygen nanobubbles-embedded hydrogel (ONB-G) with carbopol for oxygenation of wounds to accelerate the wound healing process. We integrate carbopol hydrogel and dextran-based ONBs, to prepare ONB-G that can hold oxygen and release it to accelerate wound healing. Oxygen release tests showed that the proposed ONB-G could maintain oxygen in the hydrogels for up to 34 days. Also, fluorescence studies indicated that the ONB-G could maintain the high oxygen levels for up to 8 weeks. Histological evaluation of tissues with a pig model with incision and punch wounds showed that treatment with ONB-G exhibited improved healing compared with hydrogel without ONBs or treated without gel. Our studies show that dextran-shell ONBs embedded in a gel (ONB-G) has the potential to accelerate wound healing given its oxygen holding capacity and release properties.

The present invention refers to a composition comprising: a) a crosslinked hydrophilic polymer containing amino functional groups, and b) a swelling agent, wherein the crosslinked hydrophilic polymer a) is obtainable by reacting a hydrophilic polymer containing amino functional groups with a crosslinking agent which contains at least two epoxide functional groups. The invention also refers to a method for preparing said composition and uses thereof in medical applications.

Biodegradable, cross-linked polymer particle embolics and methods of making the same are described. The particle embolics can be used as embolization agents.

A biocompatible polymeric composition for cross-linking in-situ in a wound is disclosed comprising 1) one or more polyanionic polymers such as alginates or hyaluronates, able to be cross-linked the surface of the wound and 2) one or more polycationic polymers such as chitosan or DEAE-Dextran, that assists in the solidification process as well as speeds up hemostasis without the need for applying pressure. The biocompatible polymeric composition may further comprise a cross-linking agent such as aqueous calcium chloride. The invention encompasses an initial polymeric composition, the solidified matrix cross-linked and integrated at the wound site, including the methods of using, applying, and cross-linking the composition.

According to some aspects of the invention a method for creation of a wound covering with haemostatic action includes: applying to an open wound a cell structure (grid)-forming water-soluble haemostatic composition designated as a Hemoblok consisting of a polyacrylic matrix as an active ingredient, where the matrix includes one or more polymeric carboxylic acid of a predetermined average molecular weight range, and a bactericidal agent; creating by Hemoblok on a wound surface a structure clot formation with blood plasma proteins, including albumin; creating by Hemoblok on the wound, a covering containing albumin molecules in cells of a polyacrylic structure matrix (grid), which is a primary organizer of sustainable grid structure clot film; further supplying of Hemoblok on an open wound surface to form a multilayered solid grid structure film; terminating of Hemoblok supply on a wound surface with following gradual replacement of a surface structure hemoblok-protein by fibrin.

According to some aspects of the invention a method for creation of a wound covering with haemostatic action includes: applying to an open wound a cell structure (grid)-forming water-soluble haemostatic composition designated as a Hemoblok consisting of a polyacrylic matrix as an active ingredient, where the matrix includes one or more polymeric carboxylic acid of a predetermined average molecular weight range, and a bactericidal agent; creating by Hemoblok on a wound surface a structure clot formation with blood plasma proteins, including albumin; creating by Hemoblok on the wound, a covering containing albumin molecules in cells of a polyacrylic structure matrix (grid), which is a primary organizer of sustainable grid structure clot film; further supplying of Hemoblok on an open wound surface to form a multilayered solid grid structure film; terminating of Hemoblok supply on a wound surface with following gradual replacement of a surface structure hemoblok-protein by fibrin.

The present invention relates to debriding compositions in the form of an aqueous gel. Particularly, the present invention relates to a debriding composition comprising a proteolytic enzyme mixture obtained from bromelain present in a dry form, and an aqueous gel carrier, wherein, prior to use, the proteolytic enzyme mixture being admixed with the aqueous gel carrier to form a debriding composition useful for debridement and treatment of c wounds.

The present invention relates to debriding compositions in the form of an aqueous gel. Particularly, the present invention relates to a debriding composition comprising a proteolytic enzyme mixture obtained from bromelain present in a dry form, and an aqueous gel carrier, wherein, prior to use, the proteolytic enzyme mixture being admixed with the aqueous gel carrier to form a debriding composition useful for debridement and treatment of c wounds.